ABIONYX Pharma Completes a Capital Increase in Favor of Categories of Persons
October 06 2023 - 12:30AM
Business Wire
Financial visibility extended to Q1 2025
without drawing on the equity-linked financing facility
Regulatory News:
ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME
eligible), a new generation biotech company dedicated to the
discovery and development of innovative therapies based on the
world's only recombinant apoA-1, announces the successful
completion of a capital increase of around €3,000,000 (including
premium) designed to strengthen the Company's cash position in the
context of its development in sepsis.
Terms and conditions of the issue
Following the decision to issue taken by the Board of Directors
on October 5, the Chief Executive Officer noted today the full
subscription of 2,967,352 new shares at a price of €1.011 per share
(i.e., a 10% discount to the weighted average share price of
€1.1233 for the 10 trading sessions preceding the Board of
Directors' decision). This issue represents approximately 10.21% of
the share capital at the date of the decision to issue.
This operation takes place within the framework of a capital
increase with cancellation of preferential subscription rights in
favor of persons belonging to specified categories1, decided by the
Board of Directors on October 5, acting based on the delegation
granted by the Annual General Meeting of June 27, 2023, under its
20th extraordinary resolution.
The total amount of the capital increase is €2,999,992.87
(including a par value of €148,367.60 and an issue premium of
€2,851,625.27). The new shares will carry dividend rights, will be
assimilated to existing shares and will enjoy the same rights. They
will be subject to all the provisions of the Company's bylaws and
will be admitted to trading on Euronext on the same line as
existing shares.
Share ownership
The number of shares issued represents around 10.21% of the
number of shares in circulation before issue and 9.27% after issue.
By way of illustration, a shareholder who held a number of shares
representing 1% of ABIONYX Pharma's share capital before the issue,
represents 0.91% of the share capital after the issue.
Shareholders* before and after capital increase in % of
capital
Shareholders
Before Capital
increase
% of capital
After capital increase
% of capital
Domundi SC (represented by
Mr.
Emmanuel Huynh)
3,320,198
11.43%
4,348,882
13.58%
Cyrille Tupin
1,592,214
5.48%
1,592,214
4.97%
Sadok Belmokhtar
1,859,098
6.40%
1,859,098
5.81%
BPI Participations (FR)
1,630,451
5.61%
1,630,451
5.09%
Jean-Louis Dasseux
1,286,781
4.18%
1,286,781
4.02%
Luc Demarre
1,104,619
3.80%
1,846,457
5.77%
Free float
16,577,874
56.98%
17,754,049
55.44%
TOTAL
29,057,059
100%
32,024,411
100%
* Based on information brought to the Company's attention, in
particular for bearer shareholders via declarations of crossing
thresholds (legal and statutory)
Purpose of the fundraising
The purpose of this fundraising is to strengthen the Company's
cash position in the context of its development in sepsis, and to
ensure its financial visibility, which has now been extended to Q1
2025 without drawing on the equity-linked financing facility.
Absence of prospectus
In accordance with the provisions of Article 211-3 of the
General Regulations of the Autorité des Marchés Financiers (AMF),
the issue will not be subject to a prospectus submitted for AMF
approval.
Risk factors
Risk factors are described in the 2022 Universal Registration
Document (chapter 3) filed with the AMF under number D.23-0382 on
April 28, 2023, and available on the Company's website:
www.abionyx.com and that of the AMF: www.amf-france.org.
About ABIONYX Pharma
ABIONYX Pharma is a new generation biotech company that aims to
contribute to health through innovative therapies in indications
where there is no effective or existing treatment, even the rarest
ones. Thanks to its partners in research, medicine,
biopharmaceuticals and shareholding, the company innovates on a
daily basis to propose drugs for the treatment of renal and
ophthalmological diseases, or new apoA-I vectors used for targeted
drug delivery.
________________________
1 The categories of persons covered by
this issue are as follows:
(i) individuals or legal entities
(including companies), investment companies, trusts, investment
funds or other investment vehicles of any kind, under French or
foreign law, investing on a regular basis in the pharmaceutical,
biotechnology, disease treatment or medical technology sectors;
and/or (ii) companies, institutions or entities of any kind, French
or foreign, conducting a significant proportion of their business
in the sectors referred to in (i) ; and/or (iii) French or foreign
investment services providers with an equivalent status, who may
guarantee the completion of a capital increase intended to be
placed with the persons referred to in (i) and (ii) above and, in
this context, subscribe to the securities issued; and/or (iv)
Corporate officers (including managers), employees and members of
any committee of the Company or any of its subsidiaries, as well as
any person (natural or legal) bound by a service or consultancy
contract with the Company or any of its subsidiaries.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231005965251/en/
NewCap Investor relations Nicolas Fossiez Louis-Victor
Delouvrier abionyx@newcap.eu +33 (0)1 44 71 98 53
NewCap Media relations Arthur Rouillé abionyx@newcap.eu
+33 (0)1 44 71 00 15
Abionyx Pharma (EU:ABNX)
Historical Stock Chart
From Apr 2024 to May 2024
Abionyx Pharma (EU:ABNX)
Historical Stock Chart
From May 2023 to May 2024